

Supplementary Table 2. Six-month clinical outcomes

Characteristic	Evolocumab group (n = 50)	Non-evolocumab group (n = 45)	<i>p</i> value
All death	1 (2.0)	3 (6.7)	0.435
Cardiac death	1 (2.0)	2 (4.4)	0.212
Myocardial infarction	1 (2.0)	0 (0)	0.739
Stroke	1 (2.0)	3 (6.7)	0.156
Hemorrhagic stroke	0 (0)	2 (4.4)	0.358
All revascularization	2 (4.0)	1 (2.2)	0.316
All bleeding	1 (2.0)	3 (6.7)	0.619
TIMI major	0 (0)	2 (4.4)	0.239
TIMI minor	1 (2.0)	1 (2.2)	0.875
Myalgia	2 (4.0)	1 (2.2)	0.538
Fatigue	1 (2.0)	1 (2.2)	0.812

Values are presented as number (%).

TIMI, Thrombolysis in Myocardial Infarction classification.